Akebia Therapeutics (AKBA) Misses Q4 EPS by 5c

Akebia Therapeutics (NASDAQ: AKBA) reported Q4 EPS of ($0.05), $0.05 worse than the analyst estimate of $0.00. Revenue for the quarter came in at $57.62 million versus the consensus estimate of $56.18 million.

For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.

You May Also Be Interested In

• Carnival Corp. (CCL) Tops Q2 EPS by 8c, Beats on Revenue; Offers Guidance
• Lockheed Martin bids for NATO modeling and simulation contract
• Gridline integrates Hamilton Lane data into its AI diligence tool